First Time Loading...

Ardelyx Inc
NASDAQ:ARDX

Watchlist Manager
Ardelyx Inc Logo
Ardelyx Inc
NASDAQ:ARDX
Watchlist
Price: 6.43 USD 0.63% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

Ardelyx, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one ARDX stock under the Base Case scenario is 13.63 USD. Compared to the current market price of 6.43 USD, Ardelyx Inc is Undervalued by 53%.

Key Points:
ARDX Intrinsic Value
Base Case
13.63 USD
Undervaluation 53%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Ardelyx Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ARDX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ardelyx Inc

Provide an overview of the primary business activities
of Ardelyx Inc.

What unique competitive advantages
does Ardelyx Inc hold over its rivals?

What risks and challenges
does Ardelyx Inc face in the near future?

Has there been any significant insider trading activity
in Ardelyx Inc recently?

Summarize the latest earnings call
of Ardelyx Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ardelyx Inc.

Provide P/S
for Ardelyx Inc.

Provide P/E
for Ardelyx Inc.

Provide P/OCF
for Ardelyx Inc.

Provide P/FCFE
for Ardelyx Inc.

Provide P/B
for Ardelyx Inc.

Provide EV/S
for Ardelyx Inc.

Provide EV/GP
for Ardelyx Inc.

Provide EV/EBITDA
for Ardelyx Inc.

Provide EV/EBIT
for Ardelyx Inc.

Provide EV/OCF
for Ardelyx Inc.

Provide EV/FCFF
for Ardelyx Inc.

Provide EV/IC
for Ardelyx Inc.

Show me price targets
for Ardelyx Inc made by professional analysts.

What are the Revenue projections
for Ardelyx Inc?

How accurate were the past Revenue estimates
for Ardelyx Inc?

What are the Net Income projections
for Ardelyx Inc?

How accurate were the past Net Income estimates
for Ardelyx Inc?

What are the EPS projections
for Ardelyx Inc?

How accurate were the past EPS estimates
for Ardelyx Inc?

What are the EBIT projections
for Ardelyx Inc?

How accurate were the past EBIT estimates
for Ardelyx Inc?

Compare the revenue forecasts
for Ardelyx Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ardelyx Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ardelyx Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ardelyx Inc compared to its peers.

Compare the P/E ratios
of Ardelyx Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ardelyx Inc with its peers.

Analyze the financial leverage
of Ardelyx Inc compared to its main competitors.

Show all profitability ratios
for Ardelyx Inc.

Provide ROE
for Ardelyx Inc.

Provide ROA
for Ardelyx Inc.

Provide ROIC
for Ardelyx Inc.

Provide ROCE
for Ardelyx Inc.

Provide Gross Margin
for Ardelyx Inc.

Provide Operating Margin
for Ardelyx Inc.

Provide Net Margin
for Ardelyx Inc.

Provide FCF Margin
for Ardelyx Inc.

Show all solvency ratios
for Ardelyx Inc.

Provide D/E Ratio
for Ardelyx Inc.

Provide D/A Ratio
for Ardelyx Inc.

Provide Interest Coverage Ratio
for Ardelyx Inc.

Provide Altman Z-Score Ratio
for Ardelyx Inc.

Provide Quick Ratio
for Ardelyx Inc.

Provide Current Ratio
for Ardelyx Inc.

Provide Cash Ratio
for Ardelyx Inc.

What is the historical Revenue growth
over the last 5 years for Ardelyx Inc?

What is the historical Net Income growth
over the last 5 years for Ardelyx Inc?

What is the current Free Cash Flow
of Ardelyx Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ardelyx Inc.

Financials

Balance Sheet Decomposition
Ardelyx Inc

Current Assets 246.1m
Cash & Short-Term Investments 184.3m
Receivables 22m
Other Current Assets 39.8m
Non-Current Assets 51.5m
PP&E 6.6m
Other Non-Current Assets 44.9m
Current Liabilities 50.4m
Accounts Payable 11.1m
Accrued Liabilities 30m
Other Current Liabilities 9.2m
Non-Current Liabilities 80.4m
Long-Term Debt 49.8m
Other Non-Current Liabilities 30.5m
Efficiency

Earnings Waterfall
Ardelyx Inc

Revenue
124.5m USD
Cost of Revenue
-17.8m USD
Gross Profit
106.7m USD
Operating Expenses
-169.9m USD
Operating Income
-63.3m USD
Other Expenses
-2.8m USD
Net Income
-66.1m USD

Free Cash Flow Analysis
Ardelyx Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ARDX Profitability Score
Profitability Due Diligence

Ardelyx Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
38/100
Profitability
Score

Ardelyx Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

ARDX Solvency Score
Solvency Due Diligence

Ardelyx Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
58/100
Solvency
Score

Ardelyx Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARDX Price Targets Summary
Ardelyx Inc

Wall Street analysts forecast ARDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARDX is 13.66 USD with a low forecast of 11.11 USD and a high forecast of 16.8 USD.

Lowest
Price Target
11.11 USD
73% Upside
Average
Price Target
13.66 USD
112% Upside
Highest
Price Target
16.8 USD
161% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ARDX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ARDX Price
Ardelyx Inc

1M 1M
-16%
6M 6M
+81%
1Y 1Y
+39%
3Y 3Y
-26%
5Y 5Y
+94%
10Y 10Y
-54%
Annual Price Range
6.43
52w Low
3.23
52w High
9.74
Price Metrics
Average Annual Return 38.7%
Standard Deviation of Annual Returns 102.85%
Max Drawdown -94%
Shares Statistics
Market Capitalization 1.5B USD
Shares Outstanding 232 690 000
Percentage of Shares Shorted 15.3%

ARDX Return Decomposition
Main factors of price return

What is price return decomposition?

ARDX News

Last Important Events
Ardelyx Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Ardelyx Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Ardelyx Inc Logo
Ardelyx Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Ardelyx, Inc. is a biopharmaceutical company. The company is headquartered in Fremont, California and currently employs 86 full-time employees. The company went IPO on 2014-06-19. The firm focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The firm's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of hyperphosphatemia, a condition of elevated levels of phosphate in the blood, common among patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Contact

CALIFORNIA
Fremont
34175 Ardenwood Blvd
+15107457047.0
https://www.ardelyx.com/

IPO

2014-06-19

Employees

86

Officers

President, CEO & Director
Mr. Michael G. Raab
Chief Commercial Officer
Ms. Susan Rodriguez
Chief Medical Officer
Dr. Laura A. Williams M.D., M.P.H.
Chief Financial & Operations Officer and Treasurer
Mr. Justin A. Renz CPA, MBA
Senior VP of Finance & Chief Accounting Officer
Mr. Robert Felsch
Chief Legal & Administrative Officer and Secretary
Ms. Elizabeth A. Grammer Esq.
Show More
Vice President of Corporate Communications & Investor Relations
Ms. Caitlin Lowie
Chief Human Resources Officer
Ms. Charon Spencer Sr.
Chief Development Officer
Mr. David P. Rosenbaum
Chief Regulatory Affairs & Quality Assurance Officer
Mr. Robert C. Blanks
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARDX stock?

The intrinsic value of one ARDX stock under the Base Case scenario is 13.63 USD.

Is ARDX stock undervalued or overvalued?

Compared to the current market price of 6.43 USD, Ardelyx Inc is Undervalued by 53%.